Cover Image
市場調查報告書

全球醫藥品產業及生物科技產業交易的權利金比率趨勢:2005∼2015年

Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2016

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 331922
出版日期 內容資訊 英文 319 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球醫藥品產業及生物科技產業交易的權利金比率趨勢:2005∼2015年 Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2016
出版日期: 2016年09月01日 內容資訊: 英文 319 Pages
簡介

本報告提供2010年之後的生物醫藥品產業的權利金比率趨勢,權利金結構分析,2005年之後公佈的權利金比率的授權契約概要等彙整資料。

摘要整理

第1章 簡介

  • 所謂權利金
  • 權利金比率的歷史
  • 醫藥品、生物科技產業的權利金
  • 權利金和收益佔有率
  • 本報告概要

第2章 醫藥品、生物科技產業的權利金比率概要

  • 2005∼2015年的權利金比率趨勢
  • 醫藥品、生物科技產業中公佈的權利金比率
  • 收益佔有率趨勢
  • 近幾年的文獻檢討
  • 未來的權利金比率

第3章 醫藥品、生物科技產業聯盟的平均權利金比率

  • 早期交易的權利金比率
  • 各開發階段權利金比率
  • 各治療領域權利金比率

第4章 醫藥品、生物科技產業交易的權利金條款

  • 聯盟契約結構
  • 典型性的權利金條款結構
  • 權利金條款的案例

第5章 積極地公佈權利金比率的企業

  • 權利金比率公佈最積極的企業
  • 各權利金比率前幾名聯盟契約
  • 權利金比率公佈的生物醫藥品、生物科技所扮演的角色
  • 收益佔有率聯盟契約

第6章 權利金比率契約名錄

  • 值得注意的契約文件內的權利金比率的檢驗
  • 企業A-Z
  • 各開發階段
  • 各治療標的
  • 各技術

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2013

Essential Benchmark Data for Dealmakers - The ‘Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2016’ report is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments

The ‘Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010- 2016’ report is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.

This report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of partnering deals disclosing royalty rates from 2010 to 2016.

The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all partnering deals announced since 2005 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2010. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2010, including a summary of the recent literature on the subject.

Chapter 3 provides an average benchmark royalty rates. The chapter includes numerous tables and figures summarizing the benchmark royalty rates by stage of development, therapy area and technology area.

Chapter 4 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal. The chapter includes numerous case studies for actual deals where royalty rates have been disclosed.

Chapter 5 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates, and why.

Chapter 6 provides comprehensive and detailed access to deals which disclose a royalty rate since 2010 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate.

In addition the report includes a comprehensive appendix listing of all deals where a royalty rate has been disclosed announced since 2010. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous table and figures that illustrate the trends in royalty rates in pharma and biotech deal making since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector.

Key benefits

‘Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010- 2016’ provides the reader with the following key benefits:

  • In-depth understanding of royalty rate partnering deal trends since 2010
  • Analysis of the structure of royalty clauses with numerous real life case studies
  • Comprehensive listing of all partnering deals since 2010 where a royalty rate is disclosed, together with deal terms, value and press release
  • Comprehensive access to actual partnering deal contracts entered into by the world's life science companies where a royalty rate is disclosed
  • Insight into the royalty terms included in a licensing agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

‘Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010- 2016’ is intended to provide the reader with an in-depth understanding of the royalty rate trends and structure of deals entered into by leading life science companies worldwide.

Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010- 2016 includes:

  • Trends in royalty rates in the biopharma industry since 2010
  • Analysis of royalty rate clause structure
  • Case studies of real-life licensing deals which disclose royalty rates
  • Comprehensive listing of licensing deals which disclose royalty rates since 2010
  • Access to licensing contract documents which disclose royalty rates
  • The leading licensing deals by royalty rate value since 2010
  • Most active royalty rate disclosures since 2010

In ‘Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010- 2016’ available deals and contracts are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

The ‘Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010- 2016’ report provides comprehensive access to available contract documents for licensing deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise royalty rates granted?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2016’ provides the reader with the following key benefits:

  • In-depth understanding of royalty rate partnering deal trends since 2010
  • Analysis of the structure of royalty clauses with numerous real life case studies
  • Comprehensive listing of all partnering deals since 2010 where a royalty rate is disclosed, together with deal terms, value and press release
  • Comprehensive access to actual partnering deal contracts entered into by the world's life science companies where a royalty rate is disclosed
  • Insight into the royalty terms included in a licensing agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

  • 1.1. What are royalties?
  • 1.2. History of royalty rates
  • 1.3. Royalties in pharma and biotech
  • 1.4. Royalties versus revenue share
  • 1.5. Overview of the report

Chapter 2 - An overview of pharma and biotech royalty rates

  • 2.1. Trends in royalty rates 2010-2015
  • 2.2. Royalty rate disclosure in pharma and biotech
  • 2.3. How do revenue shares figure?
  • 2.4. A review of recent literature
  • 2.5. Royalty rates in the future

Chapter 3 - Average royalty rates for pharma and biotech partnering

  • 3.1. Royalty rates in early stage deals
  • 3.2. Royalty rates by stage of development
  • 3.3. Royalty rates by therapy area

Chapter 4 - The royalty clause in pharma and biotech deals

  • 4.1. Partnering agreement structure
  • 4.2. Structure of a typical royalty clause
  • 4.3. Example royalty clauses
    • 4.3.1. Case study 1: Merck Serono-Opexa Therapeutics
    • 4.3.2. Case study 2: Aradigm - Grifols
    • 4.3.3. Case study 3: Forect Laboratories - Trevena
    • 4.3.4. Case study 4: Sage Therapeutics - University of California

Chapter 5 - Companies actively disclosing royalty rates

  • 5.1. Fifty most active companies in disclosing royalty rates
  • 5.2. Top partnering deals by royalty rate
  • 5.3. The role of bigpharma and bigbiotech in royalty rate disclosure
  • 5.2. Top partnering deals by royalty rate

Chapter 6 - Royalty rate contract directory

  • Explore royalty rates within the deal contract document to gain greater insight

Appendices

  • Appendix 1 - Royalty rates in deals - by company A-Z
  • Appendix 2 - Royalty rates in deals - by therapy area
  • Appendix 3 - Royalty rates in deals - by stage of development at signing
  • Appendix 4 - Royalty rates in deals - by technology type
  • Appendix 5 - Royalty rate references
  • Appendix 6 - Resources
  • Appendix 7 - Deal type definitions
  • Appendix 8 - Example royalty rate deal contract document

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

TABLE OF FIGURES

  • Figure 1: Trends in pharma and biotech royalty rates, 2010- 2016
  • Figure 2: Royalty rates in early stage at deal signing - 2010- 2016
  • Figure 3: Royalty rates by phase of development at deal signing - 2010- 2016
  • Figure 4: Royalty rates by therapy area - 2010- 2016
  • Figure 5: Components of the partnering deal structure
  • Figure 6: Components of the partnering royalty clause
  • Figure 7: Most active companies disclosing royalty rate 2010- 2016
  • Figure 8: Top deals by royalty rate 2010- 2016
  • Figure 9: Deals disclosing revenue share 2010- 2016
  • Figure 10: Online partnering resources
  • Figure 11: Deal type definitions
  • Figure 12: Licensing agreement for rhAAT - rEVO Biologics, LFB Biotechnologies
Back to Top